The expression profiles of these markers have led to three main clinical breast cancer subgroups for which treatment regimes are based; ER + /HER2-, HER2 + or triple-negative breast cancer (TNBC) which lack ER, PR and HER2 expression3,4. Here, ESR1 is linked to triple-negative breast carcinoma.